Verrica Pharmaceuticals Inc. / Fundamentals
Income statement
- Net revenue
€12.54M - Cost of goods sold
€1.55M - Gross profit
€10.99M - SG&A expenses
€37.24M - R&D expenses
€6.57M - EBITDA
-€33.55M - D&A
€677.24K - EBIT
-€33.04M - Interest expenses
€7.73M - EBT
-€41.45M - Tax expenses
€0.00 - Net income
-€41.45M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€3.76M - Changes in working capital
-€3.99M - Operating cash flow
-€40.38M - Capex
€13.65K - Other investing cash flow
€6.82K - Net investing cash flow
-€6.82K - Total cash dividends paid
€0.00 - Issuance of common stock
€33.67M - Debt repayment
-€5.03M - Other financing cash flow
-€1.70M - Net financing cash flow
€26.29M - Foreign exchange effects
€0.00 - Net change in cash
-€14.10M - Cash at end of period
€13.13M - Free cash flow
-€40.37M
Balance sheet
- Cash and cash equivalents
€13.13M - Cash and short-term investments
€13.13M - Total receivables
€14.82M - Inventory
€2.15M - Other current assets
€1.27M - Total current assets
€31.37M - Property, plant & equipment
€1.66M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€320.71K - Total non-current assets
€1.98M - Total assets
€33.36M - Accounts payable
€1.98M - Short-term debt
€11.36M - Other current liabilities
€11.17M - Total current liabilities
€24.92M - Long-term debt
€21.81M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€1.53M - Total non-current liabilities
€23.34M - Total liabilities
€48.27M - Common stock
€852.95 - Retained earnings
-€270.01M - Other equity
€0.00 - Total equity
-€14.91M - Total liabilities and shareholders' equity
€33.36M
Company information
- Market capitalization
€41.12M - Employees
71 - Enterprise Value
€40.62M
Company ratios
- Gross margin
-
87.6% Much better than peer group: -77,956,712,646,574.2% - EBITDA margin
-
-267.5% Much better than peer group: -428,658,253,196,194.0% - EBIT margin
-
-263.4% Much better than peer group: -432,659,954,704,748.3% - EBT margin
-
-330.5% Much better than peer group: -432,146,526,527,559.8% - Net margin
-
-330.5% Much better than peer group: -432,146,526,577,175.2% - ROE
-
278.0% Much better than peer group: -52.6% - ROA
-
-124.3% Much worse than peer group: -52.1% - Asset turnover
-
37.6% Much better than peer group: 12.9% - FCF margin
-
-322.1% Much better than peer group: -360,072,653,318,416.9% - FCF yield
-98.2% - Efficiency ratio
367.5% - Net sales per employee
-
€176.64K - Net income per employee
-
-€583.85K